Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Malignant Pleural Mesothelioma (MPM)
share announcement

Malignant Pleural Mesothelioma (MPM)

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 27494

Special Issue Editors

Dr. Giulia M. Stella

E-Mail Website
Guest Editor
1. Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy
2. Unit of Respiratory System Diseases, Cardio-Thoracic and Vascular Department, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy
Interests: thoracic cancers; personalized medicine; oncogenomics; metastatic process
Special Issues, Collections and Topics in MDPI journals
Dr. Chandra Bortolotto

E-Mail Website
Guest Editor
Radiology Department, Institute of Radiology, IRCCS Foundation Policlinico San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
Interests: thoracic imaging; lung diseases; thoracic cancers; interventional radiology; radiomics

Special Issue Information

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is a fatal asbestos-related malignancy originating in the mesothelial cells of the pleura. Whereas MPM incidence in USA has remained stable at 3000 deaths/year, rates in Europe and Japan are projected to peak in the coming years. Modern targeted therapies have so far failed in MPM. Growing evidence suggests that the unique tumor microenvironment is involved in disease onset and in inducing resistance to conventional therapies. Overall, this has led to MPM being listed as an orphan disease by the European Union (EU). The need for new therapies is therefore urgent. The aim of this Special Issue is thus to collect the state-of-the-art about the biomolecular asset of MPM, the novel omics approaches to understand, stage, and treat the disease as well as the more recent immunologically centered therapeutic regimens.

Dr. Giulia M Stella
Dr. Chandra Bortolotto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesothelioma
  • imaging
  • targeted therapies
  • immunotherapies
  • microenvironment
  • epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (8 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review, Other

3 pages, 168 KiB  
Editorial
Managing Malignant Pleural Mesothelioma in the Age of Personalized Medicine: Where Are We and What Is Still Missing?
by Giulia Maria Stella and Chandra Bortolotto
Cancers 2022, 14(22), 5540; https://doi.org/10.3390/cancers14225540 - 11 Nov 2022
Cited by 1 | Viewed by 1436
Abstract
Malignant Mesothelioma (MM) is an aggressive neoplasm of the pleural mesothelium, less frequently peritoneal and exceptionally of the vaginal tunic of the testicle and pericardium [...] Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))

Research

Jump to: Editorial, Review, Other

19 pages, 2269 KiB  
Article
Exploring MicroRNA and Exosome Involvement in Malignant Pleural Mesothelioma Drug Response
by Ben Johnson, Ling Zhuang, Emma M. Rath, Man Lee Yuen, Ngan Ching Cheng, Huaikai Shi, Steven Kao, Glen Reid and Yuen Yee Cheng
Cancers 2022, 14(19), 4784; https://doi.org/10.3390/cancers14194784 - 30 Sep 2022
Cited by 3 | Viewed by 2610
Abstract
Malignant pleural mesothelioma (MPM) is a deadly thoracic malignancy and existing treatment options are limited. Chemotherapy remains the most widely used first-line treatment regimen for patients with unresectable MPM, but is hampered by drug resistance issues. The current study demonstrated a modest enhancement [...] Read more.
Malignant pleural mesothelioma (MPM) is a deadly thoracic malignancy and existing treatment options are limited. Chemotherapy remains the most widely used first-line treatment regimen for patients with unresectable MPM, but is hampered by drug resistance issues. The current study demonstrated a modest enhancement of MPM cell sensitivity to chemotherapy drug treatment following microRNA (miRNA) transfection in MPM cell lines, albeit not for all tested miRNAs. This effect was more pronounced for FAK (PND-1186) small molecule inhibitor treatment; consistent with previously published data. We previously established that MPM response to survivin (YM155) small molecule inhibitor treatment is unrelated to basal survivin expression. Here, we showed that MPM response to YM155 treatment is enhanced following miRNA transfection of YM155-resistant MPM cells. We determined that YM155-resistant MPM cells secrete a higher level of exosomes in comparison to YM155-sensitive MPM cells. Despite this, an exosome inhibitor (GW4896) did not enhance MPM cell sensitivity to YM155. Additionally, our study showed no evidence of a correlation between the mRNA expression of inhibitor of apoptosis (IAP) gene family members and MPM cell sensitivity to YM155. However, two drug transporter genes, ABCA6 and ABCA10, were upregulated in the MPM cell lines and correlated with poor sensitivity to YM155. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))
►▼ Show Figures

Figure 1

23 pages, 3473 KiB  
Article
NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
by Haitang Yang, Sean R. R. Hall, Beibei Sun, Liang Zhao, Yanyun Gao, Ralph A. Schmid, Swee T. Tan, Ren-Wang Peng and Feng Yao
Cancers 2021, 13(7), 1561; https://doi.org/10.3390/cancers13071561 - 29 Mar 2021
Cited by 23 | Viewed by 5620
Abstract
(1) Inactivation of the tumor suppressor NF2 is believed to play a major role in the pathogenesis of malignant pleural mesothelioma (MPM) by deregulating the Hippo-YAP signaling pathway. However, NF2 has functions beyond regulation of the Hippo pathway, raising the possibility that NF2 [...] Read more.
(1) Inactivation of the tumor suppressor NF2 is believed to play a major role in the pathogenesis of malignant pleural mesothelioma (MPM) by deregulating the Hippo-YAP signaling pathway. However, NF2 has functions beyond regulation of the Hippo pathway, raising the possibility that NF2 contributes to MPM via Hippo-independent mechanisms. (2) We performed weighted gene co-expression analysis (WGCNA) in transcriptomic and proteomic datasets obtained from The Cancer Gene Atlas (TCGA) MPM cohort to identify clusters of co-expressed genes highly correlated with NF2 and phospho (p)-YAP protein, surrogate markers of active Hippo signaling and YAP inactivation. The potential targets are experimentally validated using a cell viability assay. (3) MPM tumors with NF2 loss-of-function are not associated with changes in p-YAP level nor YAP/TAZ activity score, but are characterized by a deficient B-cell receptor (BCR) signaling pathway. Conversely, MPM tumors with YAP activation display exhausted CD8 T-cell-mediated immunity together with significantly upregulated PD-L1, which is validated in an independent MPM cohort, suggesting a potential benefit of immune-checkpoint inhibitors (ICI) in this patient subset. In support of this, mutations in core Hippo signaling components including LATS2, but not NF2, are independently associated with better overall survival in response to ICI in patients. Additionally, based on cancer cell line models, we show that MPM cells with a high Hippo-YAP activity are particularly sensitive to inhibitors of BCR-ABL/SRC, stratifying a unique MPM patient subset that may benefit from BCR-ABL/SRC therapies. Furthermore, we observe that NF2 physically interacts with a considerable number of proteins that are not involved in the canonical Hippo-YAP pathway, providing a possible explanation for its Hippo-independent role in MPM. Finally, survival analyses show that YAP/TAZ scores together with p-YAP protein level, but not NF2, predict the prognosis of MPM patients. (4) NF2 loss-of-function and dysregulated Hippo-YAP pathway define distinct MPM subsets that differ in their molecular features and prognosis, which has important clinical implications for precision oncology in MPM patients. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))
►▼ Show Figures

Figure 1

18 pages, 8445 KiB  
Article
C1q–HA Matrix Regulates the Local Synthesis of Hyaluronan in Malignant Pleural Mesothelioma by Modulating HAS3 Expression
by Romana Vidergar, Andrea Balduit, Paola Zacchi, Chiara Agostinis, Alessandro Mangogna, Beatrice Belmonte, Micaela Grandolfo, Francesco Salton, Marco Biolo, Fabrizio Zanconati, Marco Confalonieri and Roberta Bulla
Cancers 2021, 13(3), 416; https://doi.org/10.3390/cancers13030416 - 22 Jan 2021
Cited by 6 | Viewed by 3453
Abstract
Increased hyaluronic acid (HA) production is often associated with cancer progression. In malignant pleural mesothelioma (MPM), HA is found at elevated levels in pleural effusions and sera of patients, and it has been widely debated whether MPM cells are able to produce HA [...] Read more.
Increased hyaluronic acid (HA) production is often associated with cancer progression. In malignant pleural mesothelioma (MPM), HA is found at elevated levels in pleural effusions and sera of patients, and it has been widely debated whether MPM cells are able to produce HA by themselves or through the release of growth factors stimulating other cells. Another key component of the MPM microenvironment is C1q, which can act as a pro-tumorigenic factor favoring cell adhesion, migration and proliferation. The aim of the current study was to prove that MPM primary cells are able to synthesize HA and to inquire the stimulus given by C1q–HA matrix to HA synthesis. We confirmed the presence of a HA coat and cable-like structures around MPM primary cells, as well as an intracellular pool, mainly localized in the cytoplasmic and perinuclear region. After evaluating HA synthase (HAS) enzymes’ basal expression in MPM primary cells, we found that C1q bound to HA was able to impinge upon HA homeostasis by upregulating HAS3 both at the mRNA and the protein levels. High expression of HAS3 has been correlated with a shorter life expectancy in MPM by bioinformatical analysis. These data confirmed that C1q bound to HA may exert pro-tumorigenic activity and identified HAS3 as a potential target in MPM. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))
►▼ Show Figures

Figure 1

13 pages, 1927 KiB  
Article
Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
by Roberta Affatato, Paolo Mendogni, Alessandro Del Gobbo, Stefano Ferrero, Francesca Ricci, Massimo Broggini and Lorenzo Rosso
Cancers 2020, 12(12), 3846; https://doi.org/10.3390/cancers12123846 - 20 Dec 2020
Cited by 5 | Viewed by 2444
Abstract
Background: Malignant pleural mesothelioma (MPM) is a very aggressive tumor originating from mesothelial cells. Although several etiological factors were reported to contribute to MPM onset, environmental exposure to asbestos is certainly a major risk factor. The latency between asbestos (or asbestos-like fibers) exposure [...] Read more.
Background: Malignant pleural mesothelioma (MPM) is a very aggressive tumor originating from mesothelial cells. Although several etiological factors were reported to contribute to MPM onset, environmental exposure to asbestos is certainly a major risk factor. The latency between asbestos (or asbestos-like fibers) exposure and MPM onset is very long. MPM continues to be a tumor with poor prognosis despite the introduction of new therapies including immunotherapy. One of the major problems is the low number of preclinical models able to recapitulate the features of human tumors. This impacts the possible discovery of new treatments and combinations. Methods: In this work, we aimed to generate patient-derived xenografts (PDXs) from MPM patients covering the three major histotypes (epithelioid, sarcomatoid, and mixed) occurring in the clinic. To do this, we obtained fresh tumors from biopsies or pleurectomies, and samples were subcutaneously implanted in immunodeficient mice within 24 h. Results: We successfully isolated different PDXs and particularly concentrated our efforts on three covering the three histotypes. The tumors that grew in mice compared well histologically with the tumors of origin, and showed stable growth in mice and a low response to cisplatin, as was observed in the clinic. Conclusions: These models are helpful in testing new drugs and combinations that, if successful, could rapidly translate to the clinical setting. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research, Other

24 pages, 792 KiB  
Review
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
by Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Roberta Alfieri and Mara Bonelli
Cancers 2021, 13(11), 2793; https://doi.org/10.3390/cancers13112793 - 4 Jun 2021
Cited by 12 | Viewed by 3786
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. The current therapeutic actions, based on cisplatin/pemetrexed treatment, are limited due to the late stage at which most patients are diagnosed and to the [...] Read more.
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. The current therapeutic actions, based on cisplatin/pemetrexed treatment, are limited due to the late stage at which most patients are diagnosed and to the intrinsic chemo-resistance of the tumor. Another relevant point is the absence of approved therapies in the second line setting following progression of MPM after chemotherapy. Considering the poor prognosis of the disease and the fact that the incidence of this tumor is expected to increase in the next decade, novel therapeutic approaches are urgently needed. In the last few years, several studies have investigated the efficacy and safety of immune-checkpoint inhibitors (ICIs) in the treatment of unresectable advanced MPM, and a number of trials with immunotherapeutic agents are ongoing in both first line and second line settings. In this review, we describe the most promising emerging immunotherapy treatments for MPM (ICIs, engineered T cells to express chimeric antigen receptors (CARs), dendritic cells (DCs) vaccines), focusing on the biological and immunological features of this tumor as well as on the issues surrounding clinical trial design. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))
►▼ Show Figures

Figure 1

Other

22 pages, 1072 KiB  
Systematic Review
New Updates of the Imaging Role in Diagnosis, Staging, and Response Treatment of Malignant Pleural Mesothelioma
by Chiara Romei, Salvatore Claudio Fanni, Federica Volpi, Alessio Milazzo, Caterina Aida D’Amore, Leonardo Colligiani, Emanuele Neri, Annalisa De Liperi, Giulia Maria Stella and Chandra Bortolotto
Cancers 2021, 13(17), 4377; https://doi.org/10.3390/cancers13174377 - 30 Aug 2021
Cited by 10 | Viewed by 3990
Abstract
Malignant pleural mesothelioma is a rare neoplasm with poor prognosis. CT is the first imaging technique used for diagnosis, staging, and assessment of therapy response. Although, CT has intrinsic limitations due to low soft tissue contrast and the current staging system as well [...] Read more.
Malignant pleural mesothelioma is a rare neoplasm with poor prognosis. CT is the first imaging technique used for diagnosis, staging, and assessment of therapy response. Although, CT has intrinsic limitations due to low soft tissue contrast and the current staging system as well as criteria for evaluating response, it does not consider the complex growth pattern of this tumor. Computer-based methods have proven their potentiality in diagnosis, staging, prognosis, and assessment of therapy response; moreover, computer-based methods can make feasible tasks like segmentation that would otherwise be impracticable. MRI, thanks to its high soft tissue contrast evaluation of contrast enhancement and through diffusion-weighted-images, could replace CT in many clinical settings. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))
►▼ Show Figures

Graphical abstract

13 pages, 13353 KiB  
Opinion
Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma
by Hélène Brossel, Alexis Fontaine, Clotilde Hoyos, Majeed Jamakhani, Mégane Willems, Malik Hamaidia and Luc Willems
Cancers 2021, 13(13), 3211; https://doi.org/10.3390/cancers13133211 - 27 Jun 2021
Cited by 5 | Viewed by 2804
Abstract
Immunotherapy based on two checkpoint inhibitors (ICI), programmed cell death 1 (PD-1, Nivolumab) and cytotoxic T-lymphocyte 4 (CTLA-4, Ipilimumab), has provided a significant improvement in overall survival for malignant mesothelioma (MM). Despite this major breakthrough, the median overall survival of patients treated with [...] Read more.
Immunotherapy based on two checkpoint inhibitors (ICI), programmed cell death 1 (PD-1, Nivolumab) and cytotoxic T-lymphocyte 4 (CTLA-4, Ipilimumab), has provided a significant improvement in overall survival for malignant mesothelioma (MM). Despite this major breakthrough, the median overall survival of patients treated with the two ICIs only reached 18.1 months vs. 14 months in standard chemotherapy. With an objective response rate of 40%, only a subset of patients benefits from immunotherapy. A critical step in the success of immunotherapy is the presentation of tumor-derived peptides by the major histocompatibility complex I (MHC-I) of tumor cells. These neoantigens are potentially immunogenic and trigger immune responses orchestrated by cytotoxic cells. In MM, tumor development is nevertheless characterized by a low mutation rate despite major structural chromosomal rearrangements driving oncogenesis (BAP1, NF2, CDKN2AB). In this opinion, we propose to investigate an approach based on the mechanisms of the DNA damage tolerance (DDT) pathways to increase the frequency of non-synonymous mutations. The idea is to transiently activate the error-prone DDT in order to generate neoantigens while preserving a fully competent antitumor immune response. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma (MPM))
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-8
Back to TopTop